Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport.

Ferré S, Quiroz C, Rea W, Guitart X, García-Borreguero D.

Adv Pharmacol. 2019;84:3-19. doi: 10.1016/bs.apha.2018.12.005. Epub 2019 Jan 18.

PMID:
31229176
2.

Biased G Protein-Independent Signaling of Dopamine D1-D3 Receptor Heteromers in the Nucleus Accumbens.

Guitart X, Moreno E, Rea W, Sánchez-Soto M, Cai NS, Quiroz C, Kumar V, Bourque L, Cortés A, Canela EI, Bishop C, Newman AH, Casadó V, Ferré S.

Mol Neurobiol. 2019 Oct;56(10):6756-6769. doi: 10.1007/s12035-019-1564-8. Epub 2019 Mar 27.

PMID:
30919214
3.

Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.

Cai NS, Quiroz C, Bonaventura J, Bonifazi A, Cole TO, Purks J, Billing AS, Massey E, Wagner M, Wish ED, Guitart X, Rea W, Lam S, Moreno E, Casadó-Anguera V, Greenblatt AD, Jacobson AE, Rice KC, Casadó V, Newman AH, Winkelman JW, Michaelides M, Weintraub E, Volkow ND, Belcher AM, Ferré S.

J Clin Invest. 2019 Mar 26;129(7):2730-2744. doi: 10.1172/JCI126912.

4.

GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells.

Jung M, Cordes S, Zou J, Yu SJ, Guitart X, Hong SG, Dang V, Kang E, Donaires FS, Hassan SA, Albitar M, Hsu AP, Holland SM, Hickstein DD, Townsley D, Dunbar CE, Winkler T.

Blood Adv. 2018 Dec 11;2(23):3553-3565. doi: 10.1182/bloodadvances.2018017137.

5.

Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis.

Garcia-Borreguero D, Guitart X, Garcia Malo C, Cano-Pumarega I, Granizo JJ, Ferré S.

Sleep Med. 2018 May;45:94-97. doi: 10.1016/j.sleep.2018.02.002. Epub 2018 Feb 24.

PMID:
29680437
6.

Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome.

Ferré S, Quiroz C, Guitart X, Rea W, Seyedian A, Moreno E, Casadó-Anguera V, Díaz-Ríos M, Casadó V, Clemens S, Allen RP, Earley CJ, García-Borreguero D.

Front Neurosci. 2018 Jan 8;11:722. doi: 10.3389/fnins.2017.00722. eCollection 2017.

7.

Targeting hypersensitive corticostriatal terminals in restless legs syndrome.

Yepes G, Guitart X, Rea W, Newman AH, Allen RP, Earley CJ, Quiroz C, Ferré S.

Ann Neurol. 2017 Dec;82(6):951-960. doi: 10.1002/ana.25104. Epub 2017 Dec 7.

8.

Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease.

Guitart X, Chern Y, Ferré S.

Oncotarget. 2017 Feb 21;8(8):12550-12551. doi: 10.18632/oncotarget.15111. No abstract available.

9.

Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.

Guitart X, Bonaventura J, Rea W, Orrú M, Cellai L, Dettori I, Pedata F, Brugarolas M, Cortés A, Casadó V, Chang CP, Narayanan M, Chern Y, Ferré S.

Neurobiol Dis. 2016 Dec;96:47-53. doi: 10.1016/j.nbd.2016.08.013. Epub 2016 Aug 24.

10.

Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer.

Guitart X, Navarro G, Moreno E, Yano H, Cai NS, Sánchez-Soto M, Kumar-Barodia S, Naidu YT, Mallol J, Cortés A, Lluís C, Canela EI, Casadó V, McCormick PJ, Ferré S.

Mol Pharmacol. 2014 Oct;86(4):417-29. doi: 10.1124/mol.114.093096. Epub 2014 Aug 5.

11.

Paraxanthine: Connecting Caffeine to Nitric Oxide Neurotransmission.

Ferré S, Orrú M, Guitart X.

J Caffeine Res. 2013 Jun;3(2):72-78.

12.

G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.

Ferré S, Casadó V, Devi LA, Filizola M, Jockers R, Lohse MJ, Milligan G, Pin JP, Guitart X.

Pharmacol Rev. 2014 Feb 10;66(2):413-34. doi: 10.1124/pr.113.008052. Print 2014. Review.

13.

Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans.

Orrú M, Guitart X, Karcz-Kubicha M, Solinas M, Justinova Z, Barodia SK, Zanoveli J, Cortes A, Lluis C, Casado V, Moeller FG, Ferré S.

Neuropharmacology. 2013 Apr;67:476-84. doi: 10.1016/j.neuropharm.2012.11.029. Epub 2012 Dec 19.

14.

Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile.

Kaddurah-Daouk R, Yuan P, Boyle SH, Matson W, Wang Z, Zeng ZB, Zhu H, Dougherty GG, Yao JK, Chen G, Guitart X, Carlson PJ, Neumeister A, Zarate C, Krishnan RR, Manji HK, Drevets W.

Sci Rep. 2012;2:667. Epub 2012 Sep 19.

15.

Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease.

Orrú M, Zanoveli JM, Quiroz C, Nguyen HP, Guitart X, Ferré S.

Exp Neurol. 2011 Nov;232(1):76-80. doi: 10.1016/j.expneurol.2011.08.005. Epub 2011 Aug 16.

16.

Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum.

Orrú M, Quiroz C, Guitart X, Ferré S.

Neuropharmacology. 2011 Oct-Nov;61(5-6):967-74. doi: 10.1016/j.neuropharm.2011.06.025. Epub 2011 Jul 5.

17.

Adenosine A(2A) Receptors and A(2A) Receptor Heteromers as Key Players in Striatal Function.

Ferré S, Quiroz C, Orru M, Guitart X, Navarro G, Cortés A, Casadó V, Canela EI, Lluis C, Franco R.

Front Neuroanat. 2011 Jun 17;5:36. doi: 10.3389/fnana.2011.00036. eCollection 2011.

18.

Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents.

Yuan P, Tragon T, Xia M, Leclair CA, Skoumbourdis AP, Zheng W, Thomas CJ, Huang R, Austin CP, Chen G, Guitart X.

Pharmacol Biochem Behav. 2011 May;98(3):349-55. doi: 10.1016/j.pbb.2011.02.001. Epub 2011 Feb 4.

19.

Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions.

Fan TW, Yuan P, Lane AN, Higashi RM, Wang Y, Hamidi AB, Zhou R, Guitart X, Chen G, Manji HK, Kaddurah-Daouk R.

Metabolomics. 2010 Jun 1;6(2):165-179.

20.

Genome-wide gene expression profiling in GluR1 knockout mice: key role of the calcium signaling pathway in glutamatergically mediated hippocampal transmission.

Zhou R, Holmes A, Du J, Malkesman O, Yuan P, Wang Y, Damschroder-Williams P, Chen G, Guitart X, Manji HK.

Eur J Neurosci. 2009 Dec;30(12):2318-26. doi: 10.1111/j.1460-9568.2009.07022.x. Epub 2009 Dec 10.

21.

Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia.

Yuan P, Zhou R, Wang Y, Li X, Li J, Chen G, Guitart X, Manji HK.

J Affect Disord. 2010 Jul;124(1-2):164-9. doi: 10.1016/j.jad.2009.10.017. Epub 2009 Nov 13.

23.

Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.

Torrens A, Mas J, Port A, Castrillo JA, Sanfeliu O, Guitart X, Dordal A, Romero G, Fisas MA, Sánchez E, Hernández E, Pérez P, Pérez R, Buschmann H.

J Med Chem. 2005 Mar 24;48(6):2080-92.

PMID:
15771450
24.

Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.

Holenz J, Mercè R, Díaz JL, Guitart X, Codony X, Dordal A, Romero G, Torrens A, Mas J, Andaluz B, Hernández S, Monroy X, Sánchez E, Hernández E, Pérez R, Cubí R, Sanfeliu O, Buschmann H.

J Med Chem. 2005 Mar 24;48(6):1781-95.

PMID:
15771424
25.

Sigma receptors: biology and therapeutic potential.

Guitart X, Codony X, Monroy X.

Psychopharmacology (Berl). 2004 Jul;174(3):301-19. Epub 2004 Jun 10. Review.

PMID:
15197533
26.

Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice.

Langa F, Codony X, Tovar V, Lavado A, Giménez E, Cozar P, Cantero M, Dordal A, Hernández E, Pérez R, Monroy X, Zamanillo D, Guitart X, Montoliu L.

Eur J Neurosci. 2003 Oct;18(8):2188-96.

PMID:
14622179
27.

GABAA receptor modulation by the novel intravenous general anaesthetic E-6375.

Pau D, Belelli D, Callachan H, Peden DR, Dunlop JI, Peters JA, Guitart X, Gutierrez B, Lambert JJ.

Neuropharmacology. 2003 Dec;45(8):1029-40.

PMID:
14614946
28.

Immunohistochemical localization of the sigma1-receptor in oligodendrocytes in the rat central nervous system.

Palacios G, Muro A, Vela JM, Molina-Holgado E, Guitart X, Ovalle S, Zamanillo D.

Brain Res. 2003 Jan 24;961(1):92-9.

PMID:
12535781
29.

Effect of the novel sigma1 receptor ligand and putative atypical antipsychotic E-5842 on BDNF mRNA expression in the rat brain.

Ovalle S, Andreu F, Pérez MP, Zamanillo D, Guitart X.

Neuroreport. 2002 Dec 3;13(17):2345-8.

PMID:
12488824
30.

Decrease of adenylyl cyclase activity and expression by a sigma1 receptor ligand and putative atypical antipsychotic.

Monroy X, Romero G, Pérez MP, Farré AJ, Guitart X.

Neuroreport. 2001 Jul 3;12(9):1989-92.

PMID:
11435935
31.
32.

Regulation of ionotropic glutamate receptor subunits in different rat brain areas by a preferential sigma(1) receptor ligand and potential atypical antipsychotic.

Guitart X, Méndez R, Ovalle S, Andreu F, Carceller A, Farré AJ, Zamanillo D.

Neuropsychopharmacology. 2000 Nov;23(5):539-46.

33.
34.

Up-regulation of sigma(1) receptor mRNA in rat brain by a putative atypical antipsychotic and sigma receptor ligand.

Zamanillo D, Andreu F, Ovalle S, Pérez MP, Romero G, Farré AJ, Guitart X.

Neurosci Lett. 2000 Mar 24;282(3):169-72.

PMID:
10717418
35.
36.
37.

Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system.

Ortiz J, Fitzgerald LW, Charlton M, Lane S, Trevisan L, Guitart X, Shoemaker W, Duman RS, Nestler EJ.

Synapse. 1995 Dec;21(4):289-98.

PMID:
8869159
38.

Extracellular signal-regulated protein kinases (ERKs) and ERK kinase (MEK) in brain: regional distribution and regulation by chronic morphine.

Ortiz J, Harris HW, Guitart X, Terwilliger RZ, Haycock JW, Nestler EJ.

J Neurosci. 1995 Feb;15(2):1285-97.

39.

Chronic morphine administration increases beta-adrenergic receptor kinase (beta ARK) levels in the rat locus coeruleus.

Terwilliger RZ, Ortiz J, Guitart X, Nestler EJ.

J Neurochem. 1994 Nov;63(5):1983-6.

PMID:
7931357
40.
41.

Second messenger and protein phosphorylation mechanisms underlying possible genetic vulnerability to alcoholism.

Nestler EJ, Guitart X, Ortiz J, Trevisan L.

Ann N Y Acad Sci. 1994 Feb 28;708:108-18. Review. No abstract available.

PMID:
8154671
43.

Individual differences in locomotor activity are associated with levels of tyrosine hydroxylase and neurofilament proteins in the ventral tegmental area of sprague-dawley rats.

Miserendino MJ, Guitart X, Terwilliger RZ, Chi S, Nestler EJ.

Mol Cell Neurosci. 1993 Oct;4(5):440-8. doi: 10.1006/mcne.1993.1055.

PMID:
19912951
44.

Alcohol-preferring and nonpreferring rats display different levels of neurofilament proteins in the ventral tegmental area.

Guitart X, Lumeng L, Li TK, Nestler EJ.

Alcohol Clin Exp Res. 1993 Jun;17(3):580-5.

PMID:
8101433
46.
47.
48.
49.

Common intracellular actions of chronic morphine and cocaine in dopaminergic brain reward regions.

Beitner-Johnson D, Guitart X, Nestler EJ.

Ann N Y Acad Sci. 1992 Jun 28;654:70-87. Review. No abstract available.

PMID:
1352957

Supplemental Content

Loading ...
Support Center